PMID- 30335819
OWN - NLM
STAT- MEDLINE
DCOM- 20190327
LR  - 20190327
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 10
DP  - 2018
TI  - Prognostic value of ErbB2/HER2 in human meningiomas.
PG  - e0205846
LID - 10.1371/journal.pone.0205846 [doi]
LID - e0205846
AB  - INTRODUCTION: Among clinical challenges regarding human meningiomas is their 
      propensity to recur even in cases with benign histology. Reliable biomarkers that 
      can identify these cases are therefore highly desired. ErbB2/HER2 status is 
      important in the medical management of patients with various human malignancies, 
      whereas its clinical relevance in human meningiomas is ambiguous. For this 
      reason, we wanted to investigate the expression of intra- and extracellular 
      domains of ErbB2/HER2 as well as the level of activated receptor in these tumors. 
      Further, we wanted to elucidate any clinicopathological associations to antibody 
      expression and if gene amplification was present. METHODS: In total, 186 human 
      meningiomas of all malignancy grades were included in the study, 163 of these 
      were in tissue microarrays (TMA). Antibody expression was assessed by means of 
      immunohistochemistry (IHC) and gene amplification by fluorescence in situ 
      hybridization (FISH). RESULTS: All cases were immunoreactive with antibodies 
      targeting the intracellular domain, whereas about 48% and 11% were positive with 
      antibodies against the extracellular domain and against the activated receptor, 
      respectively. Normal meninges were not immunoreactive. There were no relations to 
      malignancy grade, and only the activated receptor was significantly correlated 
      with increased risk for recurrence or death (time to recurrence: HR 1.568, CI 
      (1.153 to 2.132), p = 0.004). No gene amplification was found. CONCLUSION: 
      ErbB2/HER2 is generally upregulated in human meningiomas, but in an activated 
      state only in a few cases. Only the activated receptor is associated with poorer 
      prognosis, a link that needs further investigations.
FAU - Arnli, Magnus B
AU  - Arnli MB
AUID- ORCID: 0000-0002-2646-0983
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, 
      Norway.
FAU - Winther, Theo L
AU  - Winther TL
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, 
      Norway.
FAU - Lydersen, Stian
AU  - Lydersen S
AD  - Regional Centre for Child and Youth Mental Health and Child Welfare, Department 
      of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University 
      of Science and Technology (NTNU), Trondheim, Norway.
FAU - Torp, Sverre H
AU  - Torp SH
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, 
      Norway.
AD  - Department of Pathology, St. Olavs Hospital, Trondheim, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181018
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/chemistry
MH  - Biomarkers, Tumor/*genetics/immunology
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Meningeal Neoplasms/*diagnosis/genetics/mortality/surgery
MH  - Meningioma/*diagnosis/genetics/mortality/surgery
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/*diagnosis/genetics/mortality/surgery
MH  - Receptor, ErbB-2/*genetics/immunology
MH  - Survival Analysis
MH  - Tissue Array Analysis
PMC - PMC6193666
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/10/20 06:00
MHDA- 2019/03/28 06:00
PMCR- 2018/10/18
CRDT- 2018/10/19 06:00
PHST- 2018/06/11 00:00 [received]
PHST- 2018/10/02 00:00 [accepted]
PHST- 2018/10/19 06:00 [entrez]
PHST- 2018/10/20 06:00 [pubmed]
PHST- 2019/03/28 06:00 [medline]
PHST- 2018/10/18 00:00 [pmc-release]
AID - PONE-D-18-17464 [pii]
AID - 10.1371/journal.pone.0205846 [doi]
PST - epublish
SO  - PLoS One. 2018 Oct 18;13(10):e0205846. doi: 10.1371/journal.pone.0205846. 
      eCollection 2018.